SCHEMBL6486876

SCHEMBL6486876

Cc1ccccc1CNc1ccc2oc3cccnc3c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
KMT2A Q03164 6/20 0.41
MAPT P10636 6/20 0.41
KDM4E B2RXH2 4/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
HTT P42858 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
HPGD P15428 1/20 0.41
MEN1 O00255 2/20 0.41
MAOB P27338 2/20 0.41
ALB P02768 1/20 0.41
VCP P55072 1/20 0.41
LMNA P02545 3/20 0.40
ALOX12 P18054 3/20 0.40
POLB P06746 1/20 0.40
MPI P34949 1/20 0.40
HAO1 Q9UJM8 1/20 0.40
PPARG P37231 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6527731 0.86 KDM4E (0.48) ALDH1A1KMT2AMAPTKDM4EL3MBTL1
SCHEMBL6482791 0.85 KDM4E (0.42) ALDH1A1KMT2AMAPTKDM4EL3MBTL1
SCHEMBL6481670 0.83 MAOB (0.46) ALDH1A1KMT2AMAPTKDM4EHTT
SCHEMBL6483960 0.80 MAOB (0.45) ALDH1A1KMT2AMAPTKDM4EHTT
SCHEMBL6498257 0.78 PPARG (0.51) ALDH1A1KMT2AMAPTL3MBTL1HTT
SCHEMBL6483074 0.78 MAOB (0.49) ALDH1A1KMT2AMAPTL3MBTL1HTT
SCHEMBL6765690 0.74 GAA (0.45) KMT2AMAPTL3MBTL1MEN1MAOB
SCHEMBL6482983 0.73 MAOB (0.45) ALDH1A1KMT2AMAPTKDM4EHPGD
SCHEMBL6490881 0.73 MAPT (0.53) ALDH1A1KMT2AMAPTKDM4EHPGD
SCHEMBL13509561 0.72 NPC1 (0.41) ALDH1A1KMT2AMAPTKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 ALDH1A1 4486/4885KMT2A 412/4885MAPT 2337/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 ALDH1A1 4111/4885KMT2A 770/4885MAPT 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.